The House Ways and Means Committee today voted (25-14) to approve legislation to repeal the medical device excise tax for sales in calendar quarters beginning after the date of enactment (i.e., the legislation would be prospective).
All Republicans and one Democrat (Rep. Kind) on the committee voted to approve the legislation.
The Joint Committee on Taxation (JCT) has estimated that the legislation would lose approximately $24.4 billion in revenue over a 10-year period (read the JCT revenue table).
The legislation does not include any provisions to offset the cost of repealing the medical device excise tax.
The House of Representatives is expected to vote on the legislation the week of June 15. The Senate Finance Committee has not yet scheduled a markup of similar medical device excise tax repeal legislation.
The White House has not announced a position on the legislation, which would repeal one of the revenue provisions of the Affordable Care Act.
As introduced by Rep. Paulsen, H.R. 160 [PDF 249 KB] Protect Medical Innovation Act of 2015, would have repealed the excise tax on certain medical devices retroactively, effective for sales after December 31, 2012.
Chairman Ryan, however, offered an amendment in the nature of a substitute [PDF 27 KB] changing the effective date to sales in calendar quarters beginning after the date of enactment.
The Ways and Means Committee voted to approve the amendment in the nature of a substitute.
The Ways and Means Committee also voted on other (non-tax) healthcare-related bills in today’s markup.
© 2017 KPMG LLP, a Delaware limited liability partnership and the U.S. member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved.
The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.